Voyageur Pharmaceuticals Ltd. (TSE:VM) has released an update.
Voyageur Pharmaceuticals Ltd. has announced a Master Services Agreement with Applied Pharmaceutical Innovation (API) to accelerate the development and commercialization of innovative imaging contrast medium products, including a novel carbon-based MRI drug and an advanced suite of barium and iodine contrast media. The partnership aims to streamline regulatory approvals and market entry, targeting agencies like FDA and Health Canada, with a focus on oncology applications and carbon-neutral pharmaceuticals.
For further insights into TSE:VM stock, check out TipRanks’ Stock Analysis page.
